T细胞受体
生物
多重连接依赖探针扩增
异源双工
分子生物学
微小残留病
基因重排
互补决定区
多重聚合酶链反应
体细胞突变
多路复用
克隆(Java方法)
基因
底漆(化妆品)
免疫球蛋白重链
抗体
聚合酶链反应
遗传学
B细胞
免疫球蛋白轻链
T细胞
化学
白血病
免疫系统
有机化学
外显子
作者
Jacques J. M. van Dongen,Anton W. Langerak,Monika Brüggemann,Paul Evans,Michael Hummel,F. Louise Lavender,Éric Delabesse,Frédéric Davi,Ed Schuuring,Ramón García‐Sánz,J. Han van Krieken,J Droese,David González,Christian Bastard,Helen White,Marcel Spaargaren,Marcos González,A Parreira,J L Smith,Gareth J. Morgan,Michael Kneba,Elizabeth Macintyre
出处
期刊:Leukemia
[Springer Nature]
日期:2003-12-01
卷期号:17 (12): 2257-2317
被引量:2930
标识
DOI:10.1038/sj.leu.2403202
摘要
In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 multiplex PCR tubes: three VH–JH, two DH–JH, two Ig kappa (IGK), one Ig lambda (IGL), three TCR beta (TCRB), two TCR gamma (TCRG), one TCR delta (TCRD), three BCL1-Ig heavy chain (IGH), and one BCL2-IGH. The PCR products of Ig/TCR genes can be analyzed for clonality assessment by heteroduplex analysis or GeneScanning. The detection rate of clonal rearrangements using the BIOMED-2 primer sets is unprecedentedly high. This is mainly based on the complementarity of the various BIOMED-2 tubes. In particular, combined application of IGH (VH–JH and DH–JH) and IGK tubes can detect virtually all clonal B-cell proliferations, even in B-cell malignancies with high levels of somatic mutations. The contribution of IGL gene rearrangements seems limited. Combined usage of the TCRB and TCRG tubes detects virtually all clonal T-cell populations, whereas the TCRD tube has added value in case of TCRγδ+ T-cell proliferations. The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI